"Today, more than 95 per cent of Australians living with cystic fibrosis now have access to a CFTR modulator,” said Elisha Whitfield, Senior Country Manager of Vertex Pharmaceuticals Australia and New Zealand.
Vertex announces PBS listing of new once-daily treatment for cystic fibrosis
February 1, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
ARCS launches national partnership to boost public clinical research sites
May 27, 2026 - - Latest News -
Australia’s access dilemma and how commercial leaders have adapted over time
May 27, 2026 - - Latest News -
TGA approves Sanofi innovation that offers the chance to delay onset of type 1 diabetes
May 27, 2026 - - Latest News -
This unique historical oddity says all we need to know about the institution
May 26, 2026 - - Latest News -
New Zealand's Pharmac consulting on new vaccine brands and wider flu access for young children
May 26, 2026 - - Latest News -
New national survey reveals muscle health screening gap in Australian general practice
May 26, 2026 - - Latest News -
Mayne Pharma awarded legal costs as business expansion gains momentum
May 25, 2026 - - Latest News
